Asia Pacific Cell and Gene Therapy Market Forecast to 2031 - Regional Analysis - by Type, Services, Scale, Service Providers, and End User

Description

List of Tables

The Asia Pacific cell and gene therapy market was valued at US$ 1,024.37 million in 2023 and is projected to reach US$ 8,012.75 million by 2031; it is estimated to record a CAGR of 29.3% from 2023 to 2031.

Strategic Initiatives by Companies Drive Asia Pacific Cell and Gene Therapy Market

Many companies involved in manufacturing cell and gene therapy products focus on collaborations, expansions, agreements, partnerships, new product launches, and other strategic developments. These strategic initiatives help them improve sales, expand geographic reach, and enhance capacities to cater to a large customer base. A few of the significant developments in the cell and gene therapy market are; In September 2023, Agilent Technologies Inc. signed a Memorandum of Understanding (MOU) with the Advanced Cell Therapy and Research Institute, Singapore (ACTRIS). This agreement aims to improve cell and gene therapy advancements over the next three years. In March 2023, Cellevolve Bio partnered with Seattle Children's Therapeutics to develop and commercialize new multiplex CARs for pediatric cancers. With this collaboration, the companies will focus on the BrainChild research program-a suite of five multiplex CARs-to treat pediatric central nervous system (CNS) malignancies. They aim to leverage the Seattle Children's Cure Factory facility to conduct early clinical GMP research on new CARs. In March 2023, Twist Bioscience Corporation and Kriya Therapeutics, Inc. entered an antibody discovery agreement for antibodies delivered using adeno-associated viral (AAV) gene therapy in therapeutic oncology applications. Also, the companies aim to combine Twist's antibody libraries with Kriya's proprietary vector engineering platform to discover novel antibodies against specific targets of interest to be delivered with Kriya's gene therapy technology. In January 2023, FUJIFILM Corporation agreed to acquire a cell therapy manufacturing facility from Atara Biotherapeutics, Inc. The facility will witness expansion with the flexibility to produce clinical as well as commercial cell therapies, such as allogeneic T-cell and CAR T immunotherapies. The initiation of new businesses to remain competitive in the market through collaborations and partnerships can help accelerate the development of new platforms for cell and gene therapy manufacturing services. Thus, these strategic initiatives by key players are anticipated to create substantial growth opportunities in the Asia Pacific cell and gene therapy market during the forecast period.

Asia Pacific Cell and Gene Therapy Market Overview

China is making progress in gene and cell therapy. The country has a large patient population making it an attractive market for companies developing these treatments. Several companies are working on innovative therapies for diseases such as cancer and genetic disorders in China, and the country has invested heavily in gene therapy research and development. China was the first country to approve gene therapy in 2003; since then, cell and gene therapy developments have advanced rapidly worldwide, and their therapeutic potential has soared. The government of the People's Republic of China has conducted several regulatory reforms to promote the normative development of cell and gene therapies. According to a study published in Nature in 2021, China is home to more than 50% of all cell therapy trials worldwide. China has nearly 400 ongoing CAR-T trials centered on hematology, oncology, and solid tumors. Cell therapy in China is entering a new era with the approval of Fosun Kite's Yescarta and JW Therapeutics' Relma-cel in 2021 from the National Medical Products Administration (NMPA). In October 2023, CARsgen and IASO Biotherapeutics/Innovent were approved by the NMPA for new drug approvals targeting B-cell maturation antigens in CAR-T. These therapies are expected to be approved and commercialized soon.

Asia Pacific Cell and Gene Therapy Market Revenue and Forecast to 2031 (US$ Million)

Asia Pacific Cell and Gene Therapy Market Segmentation

The Asia Pacific cell and gene therapy market is categorized into type, services, scale, end user, and country.

Based on type, the Asia Pacific cell and gene therapy market is bifurcated into cell therapy and gene therapy. The cell therapy segment held a larger market share in 2023. Furthermore, the cell therapy segment is sub segmented into allogeneic, autologous, viral vectors. Additionally, the gene therapy segment is divided into non-viral vectors and viral vectors.

In terms of services, the Asia Pacific cell and gene therapy market is categorized process development, cGMP manufacturing, regulatory services, and bioassay services. The process development segment held the largest market share in 2023.

By scale, the Asia Pacific cell and gene therapy market is bifurcated into pre-commercial/R&D manufacturing and commercial scale manufacturing. The pre-commercial/R&D manufacturing segment held a larger market share in 2023.

Based on end user, the Asia Pacific cell and gene therapy market is segmented into contract research organizations, pharmaceutical and biopharmaceutical companies, and academic and research institutes. The pharmaceutical and biopharmaceutical companies segment held the largest market share in 2023.

By country, the Asia Pacific cell and gene therapy market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific cell and gene therapy market share in 2023.

Catalent Inc, Charles River Laboratories International Inc, F. Hoffmann-La Roche Ltd, FUJIFILM Holdings Corp, Lonza Group AG, Lotte Corp, Merck KGaA, Takara Bio Inc, Thermo Fisher Scientific Inc., and WuXi AppTec Co Ltd are some of the leading companies operating in the Asia Pacific cell and gene therapy market.

Product Code: BMIRE00031472

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:

4. Asia Pacific Cell and Gene Therapy Market Landscape

4.1 Overview
4.2 PEST Analysis

5. Asia Pacific Cell and Gene Therapy Market - Key Market Dynamics

5.1 Cell and Gene Therapy Market - Key Market Dynamics
5.2 Market Drivers
- 5.2.1 Increase in Number of Approval of Cell and Gene Therapies
- 5.2.2 Rapid Popularity of Outsourcing Cell and Gene Therapy Manufacturing
5.3 Market Restraints
- 5.3.1 High Cost of Cell and Gene Therapy Manufacturing
5.4 Market Opportunities
- 5.4.1 Strategic Initiatives by Companies
5.5 Future Trends
- 5.5.1 Automation of Cell and Gene Therapy Manufacturing Services
5.6 Impact of Drivers and Restraints:

6. Cell and Gene Therapy Market -Asia Pacific Market Analysis

6.1 Asia Pacific Cell and Gene Therapy Market Overview
6.2 Asia Pacific Cell and Gene Therapy Market Revenue (US$ Million), 2021-2031
6.3 Cell and Gene Therapy Market Forecast Analysis

7. Asia Pacific Cell and Gene Therapy Market Analysis - by Type

7.1 Cell Therapy
- 7.1.1 Overview
- 7.1.2 Cell Therapy: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
7.2 Gene Therapy
- 7.2.1 Overview
- 7.2.2 Gene Therapy: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)

8. Asia Pacific Cell and Gene Therapy Market Analysis - by Services

8.1 Process Development
- 8.1.1 Overview
- 8.1.2 Process Development: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
8.2 cGMP Manufacturing
- 8.2.1 Overview
- 8.2.2 cGMP Manufacturing: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
8.3 Regulatory Services
- 8.3.1 Overview
- 8.3.2 Regulatory Services: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
8.4 Bioassay Services
- 8.4.1 Overview
- 8.4.2 Bioassay Services: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)

9. Asia Pacific Cell and Gene Therapy Market Analysis - by Scale

9.1 Pre-Commercial/R&D Manufacturing
- 9.1.1 Overview
- 9.1.2 Pre-Commercial/R&D Manufacturing: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
9.2 Commercial Scale Manufacturing
- 9.2.1 Overview
- 9.2.2 Commercial Scale Manufacturing: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)

10. Asia Pacific Cell and Gene Therapy Market Analysis - by Service Providers

10.1 CDMOs
- 10.1.1 Overview
- 10.1.2 CDMOs: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
10.2 CMOs
- 10.2.1 Overview
- 10.2.2 CMOs: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)

11. Asia Pacific Cell and Gene Therapy Market Analysis - by End User

11.1 Contract Research Organizations
- 11.1.1 Overview
- 11.1.2 Contract Research Organizations: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
11.2 Pharmaceutical and Biopharmaceutical Companies
- 11.2.1 Overview
- 11.2.2 Pharmaceutical and Biopharmaceutical Companies: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
11.3 Academic and Research Institutes
- 11.3.1 Overview
- 11.3.2 Academic and Research Institutes: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)

12. Asia Pacific Cell and Gene Therapy Market - Country Analysis

12.1 Asia Pacific Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
- 12.1.1 Asia Pacific Cell and Gene Therapy Market - Revenue and Forecast Analysis - by Country
  - 12.1.1.1 Asia Pacific: Cell and Gene Therapy Market - Revenue and Forecast Analysis - by Country
  - 12.1.1.2 China: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
    - 12.1.1.2.1 China: Cell and Gene Therapy Market Breakdown, by Type
      - 12.1.1.2.1.1 China: Cell and Gene Therapy Market Breakdown, by Cell Therapy
      - 12.1.1.2.1.2 China: Cell and Gene Therapy Market Breakdown, by Gene Therapy
    - 12.1.1.2.2 China: Cell and Gene Therapy Market Breakdown, by Services
    - 12.1.1.2.3 China: Cell and Gene Therapy Market Breakdown, by Scale
    - 12.1.1.2.4 China: Cell and Gene Therapy Market Breakdown, by Service Providers
    - 12.1.1.2.5 China: Cell and Gene Therapy Market Breakdown, by End User
  - 12.1.1.3 Japan: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
    - 12.1.1.3.1 Japan: Cell and Gene Therapy Market Breakdown, by Type
      - 12.1.1.3.1.1 Japan: Cell and Gene Therapy Market Breakdown, by Cell Therapy
      - 12.1.1.3.1.2 Japan: Cell and Gene Therapy Market Breakdown, by Gene Therapy
    - 12.1.1.3.2 Japan: Cell and Gene Therapy Market Breakdown, by Services
    - 12.1.1.3.3 Japan: Cell and Gene Therapy Market Breakdown, by Scale
    - 12.1.1.3.4 Japan: Cell and Gene Therapy Market Breakdown, by Service Providers
    - 12.1.1.3.5 Japan: Cell and Gene Therapy Market Breakdown, by End User
  - 12.1.1.4 India: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
    - 12.1.1.4.1 India: Cell and Gene Therapy Market Breakdown, by Type
      - 12.1.1.4.1.1 India: Cell and Gene Therapy Market Breakdown, by Cell Therapy
      - 12.1.1.4.1.2 India: Cell and Gene Therapy Market Breakdown, by Gene Therapy
    - 12.1.1.4.2 India: Cell and Gene Therapy Market Breakdown, by Services
    - 12.1.1.4.3 India: Cell and Gene Therapy Market Breakdown, by Scale
    - 12.1.1.4.4 India: Cell and Gene Therapy Market Breakdown, by Service Providers
    - 12.1.1.4.5 India: Cell and Gene Therapy Market Breakdown, by End User
  - 12.1.1.5 Australia: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
    - 12.1.1.5.1 Australia: Cell and Gene Therapy Market Breakdown, by Type
      - 12.1.1.5.1.1 Australia: Cell and Gene Therapy Market Breakdown, by Cell Therapy
      - 12.1.1.5.1.2 Australia: Cell and Gene Therapy Market Breakdown, by Gene Therapy
    - 12.1.1.5.2 Australia: Cell and Gene Therapy Market Breakdown, by Services
    - 12.1.1.5.3 Australia: Cell and Gene Therapy Market Breakdown, by Scale
    - 12.1.1.5.4 Australia: Cell and Gene Therapy Market Breakdown, by Service Providers
    - 12.1.1.5.5 Australia: Cell and Gene Therapy Market Breakdown, by End User
  - 12.1.1.6 South Korea: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
    - 12.1.1.6.1 South Korea: Cell and Gene Therapy Market Breakdown, by Type
      - 12.1.1.6.1.1 South Korea: Cell and Gene Therapy Market Breakdown, by Cell Therapy
      - 12.1.1.6.1.2 South Korea: Cell and Gene Therapy Market Breakdown, by Gene Therapy
    - 12.1.1.6.2 South Korea: Cell and Gene Therapy Market Breakdown, by Services
    - 12.1.1.6.3 South Korea: Cell and Gene Therapy Market Breakdown, by Scale
    - 12.1.1.6.4 South Korea: Cell and Gene Therapy Market Breakdown, by Service Providers
    - 12.1.1.6.5 South Korea: Cell and Gene Therapy Market Breakdown, by End User
  - 12.1.1.7 Rest of Asia Pacific: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
    - 12.1.1.7.1 Rest of Asia Pacific: Cell and Gene Therapy Market Breakdown, by Type
      - 12.1.1.7.1.1 Rest of Asia Pacific: Cell and Gene Therapy Market Breakdown, by Cell Therapy
      - 12.1.1.7.1.2 Rest of Asia Pacific: Cell and Gene Therapy Market Breakdown, by Gene Therapy
    - 12.1.1.7.2 Rest of Asia Pacific: Cell and Gene Therapy Market Breakdown, by Services
    - 12.1.1.7.3 Rest of Asia Pacific: Cell and Gene Therapy Market Breakdown, by Scale
    - 12.1.1.7.4 Rest of Asia Pacific: Cell and Gene Therapy Market Breakdown, by Service Providers
    - 12.1.1.7.5 Rest of Asia Pacific: Cell and Gene Therapy Market Breakdown, by End User

13. Industry Landscape

13.1 Overview
13.2 Growth Strategies in Cell and Gene Therapy Market
13.3 Organic Growth Strategies
- 13.3.1 Overview
13.4 Inorganic Growth Strategies
- 13.4.1 Overview

14. Company Profiles

14.1 Thermo Fisher Scientific Inc.
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
14.2 Merck KGaA
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
14.3 Charles River Laboratories International Inc
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
- 14.3.6 Key Developments
14.4 Lonza Group AG
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
14.5 WuXi AppTec Co Ltd
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
14.6 Takara Bio Inc
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
14.7 FUJIFILM Holdings Corp
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
- 14.7.6 Key Developments
14.8 F. Hoffmann-La Roche Ltd
- 14.8.1 Key Facts
- 14.8.2 Business Description
- 14.8.3 Products and Services
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.8.6 Key Developments
14.9 Catalent Inc
- 14.9.1 Key Facts
- 14.9.2 Business Description
- 14.9.3 Products and Services
- 14.9.4 Financial Overview
- 14.9.5 SWOT Analysis
- 14.9.6 Key Developments
14.10 Lotte Corp
- 14.10.1 Key Facts
- 14.10.2 Business Description
- 14.10.3 Products and Services
- 14.10.4 Financial Overview
- 14.10.5 SWOT Analysis
- 14.10.6 Key Developments

15. Appendix

15.1 About The Insight Partners
15.2 Glossary of Terms